HCM - HUTCHMED (China) Limited Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

HCM

HUTCHMED (CHINA) LIMITED

NASDAQ

$12.38

▼ DOWN 0.28% (-0.04)

KEY STATISTICS

Market Cap$2.16 B

52w High$18.30

52w Low$9.77

Dividend Yield—

Frequency—

P/E4.64

Volume56.14K

Shares Out.174.47M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Chig Fung Cheng

ABOUT

SECTOR

Healthcare

WENT PUBLIC

March 16, 2016

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

1,796

PRICE TARGET

Target High$14.00

Target Low$13.60

Target Median$13.80

Target Consensus$13.80

UPCOMING EARNINGS

DateMar 4, 2027

DayThursday

Rev. Est.$329.08M

MAR

THU

SPLIT RECORD

DATE	TYPE	RATIO
2019-05-30	Forward	10:1

PRICE

$12.38 ▼ DOWN 0.28% (−$0.04)

OVERLAYS

About HUTCHMED (China) Limited

https://www.hutch-med.com ↗

HUTCHMED (China) Limited develops and commercializes targeted cancer and immunological therapies globally, including inhibitors like Savolitinib, Fruquintinib, and Surufatinib, through collaborations with major pharma companies.

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT HUTCHMED (CHINA) LIMITED IS KNOWN FOR

FRUZAQLA® (fruquintinib)

FRUZAQLA® is an FDA- and EU-approved oral VEGFR inhibitor launched by HUTCHMED in 2023-2024, targeting tumor angiogenesis through all three VEGFRs.

COMPETITORS

COMPETITOR

Revenue by Products

PRODUCT	Q2-2021	Q2-2022	Q2-2023	Q4-2023
Product	$129.15M	$136.93M ▲	—	—
Collaboration Research And Development	$4.79M	$12.34M ▲	$28.72M ▲	$51.68M ▲
Other Collaboration Licensing Revenue	—	$14.95M	$250.07M ▲	$28.79M ▼
Commercialization Services	$15.03M	$21.59M ▲	$25.36M ▲	$23.25M ▼
Other Collaboration Royalties Revenue	$5.82M	$14.33M ▲	$14.98M ▲	$17.49M ▲
Seroquel	—	—	$1.1M	—
Research And Development Services	$261K	$263K ▲	$246K ▼	$235K ▼